PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study

por Du, Xin-Xing, Dong, Yan-Hao, Zhu, Han-Jing, Fei, Xiao-Chen, Gong, Yi-Ming, Xia, Bin-Bin, Wu, Fan, Wang, Jia-Yi, Liu, Jia-Zhou, Fan, Lian-Cheng, Wang, Yan-Qing, Dong, Liang, Zhu, Yin-Jie, Pan, Jia-Hua, Dong, Bai-Jun, Xue, Wei
Publicado 2022